Differences

This shows you the differences between two versions of the page.

--- triaging_pdl1_3d_requests [2026/04/07 20:28] – gilbert
+++ triaging_pdl1_3d_requests [2026/04/07 20:40] (current) – removed gilbert
@@ Line 1: / Line 1: @@
-====== Biomarker Index (Quick Reference) ======
-PDL1UPPERGIMARCH2026: PD-L1 IHC (22C3) for Gastric, GEJ, and Esophageal Adenocarcinoma/ESCC
-BMCLAUDIN18: Claudin 18.2 IHC for Gastric or GEJ Adenocarcinoma
-PDL1HNSCC22C3PEMBRO: PD-L1 IHC (22C3) for Advanced HNSCC
-PDL1HNSCCNEOADPEMBRO: PD-L1 IHC (22C3) for Resectable HNSCC (Neoadjuvant)
-PDL1CERVIX: PD-L1 IHC (22C3) for Cervical Cancer (SCC/Adeno)
-MOLARCEP17: CEP17 SISH Ploidy Analysis
-PDL1NSCLCPEMBRO22C3: PD-L1 IHC (22C3) for NSCLC Stage IIIb to IV
-PDL1NSCLCATEZOSP263: PD-L1 IHC (SP263) for NSCLC Stage II to IIIA (Adjuvant)
-PDL1TNBC22C3PEMBRO: PD-L1 IHC (22C3) for Triple Negative Breast Cancer
----
-====== Detailed Biomarker Tables ======
-===== Gastrointestinal Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Gastric, GEJ, esophageal adenocarcinoma; ESCC | Pembrolizumab, Nivolumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1UPPERGIMARCH2026.pdf | ''PDL1UPPERGIMARCH2026''}} |
-| **Claudin 18.2** | Gastric or GEJ adenocarcinoma | Zolbetuximab | VENTANA CLDN18 (43-14A) %%RxDx%% | {{media:biomarkers:BMCLAUDIN18.pdf | ''BMCLAUDIN18''}} |
-</WRAP>
-===== Head & Neck Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | **Advanced** HNSCC | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1HNSCC22C3PEMBRO.pdf | ''PDL1HNSCC22C3PEMBRO''}} |
-| **PD-L1** | **Resectable** HNSCC | Pembrolizumab as **Neoadjuvant** | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1HNSCCNEOADPEMBRO.pdf | ''PDL1HNSCCNEOADPEMBRO''}} |
-</WRAP>
-===== Gyne Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Cervical cancer (SCC and Adenocarcinoma) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1CERVIX.pdf | ''PDL1CERVIX''}} |
-| **CEP17 SISH** | Ploidy Analysis | N/A | VENTANA Inform Chromosome 17 probe | {{media:biomarkers:MOLARCEP17.pdf | ''MOLARCEP17''}} |
-</WRAP>
-===== Lung Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | NSCLC stage IIIb to IV | Pembrolizumab | PDL1 22C3 | {{media:biomarkers:PDL1NSCLCPEMBRO22C3.pdf | ''PDL1NSCLCPEMBRO22C3''}} |
-| **PD-L1** | NSCLC stage II to IIIA | Atezolizumab as **Adjuvant** | PDL1 SP263 | {{media:biomarkers:PDL1NSCLCATEZOSP263.pdf | ''PDL1NSCLCATEZOSP263''}} |
-</WRAP>
-===== Breast Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Triple Negative Breast Cancer (TNBC) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1TNBC22C3PEMBRO.pdf | ''PDL1TNBC22C3PEMBRO''}} |
-</WRAP>